OPK OPKO HEALTH, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 944809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.3%
TTM net income YoY17.9%
TTM EPS YoY24.0%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-25.5%
Net margin-29.5%
FCF margin-27.0%
EBITDA margin-8.3%
Returns
ROE-12.2%
ROA-7.6%
ROIC (approx.)-12.4%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets40.6%
Debt / equity0.00x
Current ratio4.97x
Interest coverage2.08x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $65.41M | $163.58M | $124.20M | $148.45M | $56.42M | $156.81M | $149.95M | $183.64M |
| Cost of revenue | $23.35M | $83.56M | $78.44M | $84.42M | $21.37M | $107.41M | $107.33M | $98.98M |
| Gross profit | $42.06M | $80.02M | $45.76M | $64.03M | $35.05M | $49.40M | $42.62M | $84.66M |
| R&D expense | $32.18M | $33.17M | $29.20M | $32.77M | $29.80M | $30.34M | $30.84M | $30.43M |
| SG&A expense | $24.84M | $52.92M | $48.61M | $50.52M | $22.27M | $59.60M | $59.09M | $67.03M |
| Operating income | -$31.41M | -$6.97M | -$51.02M | -$38.32M | -$33.55M | -$59.98M | -$67.17M | -$33.14M |
| Interest expense | $13.45M | $11.38M | $10.94M | -$97.03M | $11.33M | $70.33M | $15.47M | $14.24M |
| Pretax income | -$42.87M | -$13.40M | -$60.96M | -$3.29M | -$40.97M | -$162.52M | -$73.37M | $34.98M |
| Income tax | -$7.31M | -$4.98M | -$6.11M | -$15.66M | -$8.05M | -$14.08M | -$5.77M | $20.95M |
| Net income | -$53.53M | -$8.42M | -$54.85M | -$31.26M | $21.63M | -$148.44M | -$67.61M | $14.03M |
| EBITDA | -$12.47M | $15.44M | -$28.82M | -$15.94M | -$15.51M | -$36.95M | -$43.68M | -$9.10M |
| EPS (basic) | -0.07 | -0.01 | -0.07 | -0.04 | 0.03 | -0.19 | -0.10 | 0.02 |
| EPS (diluted) | -0.07 | -0.01 | -0.07 | -0.04 | 0.03 | -0.19 | -0.10 | 0.01 |
| Weighted avg. shares (diluted) | 746.48M | 755.27M | 758.88M | — | 777.15M | 788.01M | 671.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $384.04M | $300.76M | $331.86M | $364.41M | $411.97M | $267.28M | $428.83M | $426.58M |
| Receivables | $80.21M | $81.89M | $79.64M | $90.25M | $94.58M | $99.38M | $96.15M | $118.02M |
| Inventory | $50.60M | $61.85M | $64.40M | $52.73M | $64.95M | $66.34M | $64.00M | $56.80M |
| Current assets | $806.28M | $500.24M | $535.36M | $581.88M | $627.13M | $583.33M | $737.60M | $662.09M |
| PP&E, net | $68.02M | $71.45M | $72.58M | $72.81M | $74.99M | $74.94M | $71.19M | $70.13M |
| Goodwill | $317.36M | $481.51M | $482.27M | $320.85M | $484.03M | $484.19M | $476.67M | $529.25M |
| Intangibles | $396.17M | $477.57M | $496.35M | $446.43M | $535.38M | $555.99M | $568.52M | $616.61M |
| Total assets | $1.88B | $1.83B | $1.86B | $1.93B | $2.00B | $1.97B | $2.13B | $2.20B |
| Current liabilities | $162.36M | $149.37M | $148.38M | $146.68M | $169.32M | $171.18M | $295.85M | $193.10M |
| Short-term debt | $1.19M | $912,000 | $1.53M | $1.74M | $1.46M | $1.52M | $1.43M | $437.20M |
| Long-term debt | $1.56M | $1.78M | $2.01M | $2.26M | $2.51M | $2.77M | $2.83M | $3.00M |
| Total debt | $2.75M | $2.69M | $3.54M | $4.00M | $3.97M | $4.29M | $4.26M | $440.20M |
| Total liabilities | $764.08M | $645.29M | $652.19M | $663.98M | $690.02M | $676.09M | $816.66M | $834.76M |
| Shareholders' equity | $1.12B | $1.18B | $1.20B | $1.27B | $1.31B | $1.30B | $1.31B | $1.37B |
| Net debt | -$381.28M | -$298.07M | -$328.33M | -$360.41M | -$408.00M | -$262.99M | -$424.57M | $13.62M |
| Cash flow statement | ||||||||
| Operating cash flow | -$36.31M | -$43.50M | -$19.31M | -$25.92M | -$34.65M | -$83.42M | -$34.55M | -$44.41M |
| Capital expenditure | $2.79M | $3.00M | $1.83M | $2.67M | $3.13M | $3.28M | $3.19M | $5.41M |
| Free cash flow | -$39.10M | -$46.50M | -$21.14M | -$28.59M | -$37.78M | -$86.70M | -$37.75M | -$49.82M |
| Investing cash flow | $11.29M | $15.54M | -$1.80M | -$2.05M | $194.65M | -$2.83M | $40.53M | $115.99M |
| Financing cash flow | $114.47M | -$13.03M | -$5.16M | -$18.34M | -$16.21M | -$79.49M | -$4.02M | -$40.47M |
| Depreciation & amortization | $18.94M | $22.41M | $22.20M | $22.37M | $18.04M | $23.03M | $23.49M | $24.04M |
| Stock-based compensation | $1.80M | $2.20M | $2.73M | $2.92M | $2.50M | $2.20M | $2.62M | $3.06M |
| Share buybacks | $10.63M | $13.02M | $4.77M | $13.51M | $15.28M | $18.25M | $0 | $16.46M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.